Evotec Investor Day Presentation Deck
1
2
3
PAGE 18
evotec
EVT Innovate platforms (Examples)
iPSC
Boehringer
Ingelheim
Neurodegeneration
UF: $45 m + $ 30 m
MS: up to $ 250 m /
product
% up to double digit
2017
BREAKPOINT
THERAPEUTICS
Indication driven target portfolios (Examples)
Multiple indications
P2X3, B1, P2X4
UF: ND
Multiple indications
MS: ND
%: Single digit
2011
novo nordisk
2009
Transactions are the beginning for risk-free value creation
Co-owned portfolio¹)- Selected examples (in € m/ US$ m)
B
BAYER
5
CKD Kidney diseases
UF: ND
MS: > € 150 m / product
% Tiered royalties
UF: € 12 m
MS: approx. € 580 m
% up to double-digit
2018
Multiple indications
R&D loan: > € 75 m
Europische investitionshank
2012
BRIDGES, operational ventures, spin-offs, grants... (Examples)
DNA Repair Spin-off
Multiple indications
Financing: > € 15 m
Financing: € 30 m
Protein degradation
oncology
2015
UF: ND
MS: up to $250 m /
product
% up to double-digit
Solid Tumors
UF: US $ 65 m
MS: ND
% up to double-digit
LAB282
2018
¹) Since 2012 - Status 2020; ND (not disclosed)
2017
2016
BAYER
2
Takeda
NephThera
PCOS
Womans 'Health
UF: € 6.5 m
MS: > € 330 m
% up to double-digit
2019
Multiple
UF: ND
MS: > € 150 m/product
%: up to double-digit
JV: CKD
Financing: > € 25 m
2017
2018
Infectious Diseases
UF: € 60 m
SANOFI MS: not applicable
%: not applicable
BAYER
長
CKD
UF: ND
MS: > € 300 m
% up to double-digit
Equitiy & JV
Financing: > $ 85 m
Exscientia
RIVEN HY KNOWLEDGE
2020
2017
2018
Upfronts
> € 200 m
Potential milestones
> € 7 bn
VC financing, R&D
loans & grants
> € 200 m
Ø Royalties on
more than 110
targets
8% (from 3 -50%)View entire presentation